TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
In the U.K. SIMPLIFIED trial, high-dose vitamin D3 did not significantly improve overall survival or several major health outcomes among 3,866 adults receiving dialysis. Researchers reported possible signals in some subgroups, but said those findings are exploratory and need further study.
High-dose vitamin D3 did not significantly improve overall survival among adults receiving dialysis for end-stage kidney disease in the SIMPLIFIED trial, according to results presented October 26 at the American Society of Nephrology Kidney Week meeting. The U.K. trial compared vitamin D supplementation with standard care in 3,866 patients, addressing whether a treatment often considered for deficiency can reduce deaths or major health events in this population.
Participants were randomly assigned to receive 60,000 international units of cholecalciferol every two weeks or standard care without trial-provided supplementation. Over a median follow-up of 7.5 years, the researchers found no statistically significant difference in overall survival. The reported conditional hazard ratio was 0.95, with a 95% confidence interval of 0.86 to 1.04 and P=0.26.
The trial recorded 1,817 deaths. It also found no significant differences in its reported secondary outcomes: fatal and nonfatal cardiovascular events, infections, fractures and malignancy. Sensitivity analyses that accounted for kidney transplantation, COVID-19 infection and stopping treatment did not change the primary survival result.
The supplement did raise vitamin D levels in the measured subset: among the first 206 participants assessed after four months, median 25-hydroxyvitamin D was 141 nmol/L in the supplementation group, compared with 36.5 nmol/L among controls. The researchers described high-dose cholecalciferol as safe and well tolerated; at least one hospital admission occurred in 69% of the intervention group and 70% of the standard-care group.
No Survival Gain From Routine High Doses
The result challenges the idea that raising vitamin D levels with a high-dose regimen will, by itself, improve survival for people on dialysis. This group faces substantial health risks: trial presenter Rona Smith of the University of Cambridge said half of people starting dialysis will not be alive by five years, and that cardiovascular disease accounts for most deaths. The trial found no significant overall survival benefit despite a marked rise in vitamin D levels in the tested participants.
For patients and clinicians, the findings do not establish that vitamin D replacement is unnecessary when someone is deficient. They address a specific approach—60,000 IU every two weeks—and whether it improved outcomes across this trial population. Smith said the findings do not support routine supplementation at that high dose to improve survival. Decisions about testing and treating deficiency remain separate from using high-dose supplements as a general strategy to prevent deaths.
A nominal reduction in major adverse cardiovascular events was reported, with a hazard ratio of 0.88 (95% CI 0.78-0.99; P=0.03), driven mainly by peripheral arterial disease events. Because the trial was not powered to confirm those individual outcomes, this result should not be treated as proof of cardiovascular protection.
Products Worth Considering
EGO POWER+ 21 Cordless Electric Lawn Mower Kit, Self-Propelled
Husqvarna Power Axe 350i 18-Inch Cordless Chainsaw Kit
Greenworks 48V (24V x 2) 21-inch Self-Propelled Lawn Mower, Battery Kit
As an affiliate, we earn on qualifying purchases.
The Evidence Gap Behind SIMPLIFIED
Vitamin D deficiency is common among people receiving dialysis, and observational studies have linked low vitamin D levels with higher mortality and other adverse outcomes. Such associations do not show that supplementation causes better outcomes. Smith said evidence from studies in the general population has also offered little support for vitamin D supplements reducing mortality or clinical events.
Kidney Disease: Improving Global Outcomes guidelines suggest measuring 25-hydroxyvitamin D in people with stage 3-5 chronic kidney disease, including those on dialysis, and replacing vitamin D when levels are deficient. Smith said the guidelines recognize that the evidence supporting this approach is low-grade. SIMPLIFIED was designed to address that evidence gap with a large pragmatic trial.
The study enrolled patients at 55 U.K. renal units. Median participant age was 65; 68% were men, 80% were white and 40% had diabetes. Nearly all participants received in-center hemodialysis, and their median time on dialysis at baseline was 2.25 years. Follow-up was largely remote after an in-person baseline visit, with outcomes drawn from routinely collected electronic health records.
Subgroup Signals Need Testing
Prespecified analyses suggested a possible benefit among men and participants of non-white ethnicity. Smith said these analyses were not powered to establish effects in those groups, so the signals are exploratory rather than definitive. She noted that non-white participants tend to have lower baseline vitamin D levels and said the finding could be explored in future research.
The reported cardiovascular signal also remains uncertain. Although the trial recorded a nominal reduction in major adverse cardiovascular events, the study was not designed to confirm associations for individual endpoints, including peripheral arterial disease. The available report does not provide subgroup effect estimates or enough detail to establish whether any particular group had a reliable treatment benefit.
The results concern the trial’s high-dose schedule and its enrolled population. They do not settle whether treating a documented deficiency benefits an individual patient, nor do they establish effects of other doses or schedules. The report says vitamin D levels were compared after four months in the first 206 participants; that measurement subset should not be mistaken for the full trial’s outcome assessment.
Further Study of Select Groups
Researchers may use the subgroup findings to shape future studies, particularly research focused on patients with lower baseline vitamin D levels. Any such work would need to test those questions directly before a benefit could be considered established. The current results, as presented at Kidney Week, do not report a change to clinical guidelines or a new recommendation for individual care.
For now, the main confirmed finding is the absence of a significant overall survival benefit from the tested high-dose regimen. The trial also found no significant difference across the listed secondary outcomes, while leaving possible subgroup and cardiovascular effects unresolved. Decisions about vitamin D testing or replacement should be made with a qualified health professional, based on a patient’s circumstances and current clinical guidance.
Key Questions
Did high-dose vitamin D improve survival in the trial?
No significant overall survival difference was found between the patients assigned 60,000 IU every two weeks and those receiving standard care without trial-provided supplementation.
How many people took part in SIMPLIFIED?
The trial randomized 3,866 adults with end-stage kidney disease receiving dialysis at 55 U.K. renal units.
Did the trial show any possible benefit?
Exploratory subgroup analyses suggested a possible signal among men and participants of non-white ethnicity. A nominal reduction in major adverse cardiovascular events was also reported. Researchers cautioned that the study was not powered to confirm these findings.
Does this mean dialysis patients should not take vitamin D?
The trial tested one high-dose schedule and did not show a survival benefit across the overall study group. It does not determine whether a particular patient should receive replacement for a documented deficiency. Patients should discuss testing and treatment with a qualified health professional.
Source: medpagetoday.com
